Skin Irritation Clinical Trial
Official title:
A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Corplex™ Donepezil Transdermal Delivery System
Verified date | September 2018 |
Source | Corium International Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)
Status | Completed |
Enrollment | 256 |
Est. completion date | April 2, 2018 |
Est. primary completion date | March 8, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Healthy, adult, male or female - Body mass index = 18.0 and = 35.0 kg/m2 - Medically healthy, as deemed by the Investigator - Have a skin type with Fitzpatrick scale score of I, II, or III Exclusion Criteria: - History or presence of alcoholism or drug abuse - History or presence of hypersensitivity or idiosyncratic reaction to the study product or related compounds - Positive urine drug or alcohol results - Female subjects with a positive pregnancy test or who are lactating - Any of the following drugs, but not limited to, for 30 days prior to the first dose of study product treatment on Day 1 and throughout the study: 1. Inducers of cytochrome enzymes and/or P-glycoprotein 2. Anti-inflammatory drugs or cyclooxygenase 2 analgesics 3. Beta-blockers 4. Cholinergics and anticholinergics 5. Muscle relaxants, anti-Parkinsonian, or neuroleptic medications - History or presence of significant skin damage deemed by the investigator to potentially interfere - Any medical or surgical procedure or trauma - Participation in another clinical study within 30 days or 5 times the half-life of the investigational product (whichever is longer) prior to the first study product treatment |
Country | Name | City | State |
---|---|---|---|
United States | Celerion Inc. | Lincoln | Nebraska |
United States | Celerion Inc. | Phoenix | Arizona |
Lead Sponsor | Collaborator |
---|---|
Corium International Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Cumulative Skin Irritation Score of Donepezil Corplex TDS (Induction Phase) | Mean Cumulative skin irritation score is determined by averaging the combined Dermal Response score (8-point categorical scale using numeric values) and the Other Effects score (6-point categorical scale using alphabet letters equivalent to numeric values) during the induction phase of the study. | Induction (21 days) | |
Primary | Number of Subjects with Skin sensitization potential of Corplex TDS (Challenge Phase) | Subject's sensitization potential will be assessed using the combined Dermal Response score (8-point categorical scale using numeric values) and the Other Effects score (6-point categorical scale using alphabet letters equivalent to numeric values) . The last of 48 hr or 72 hr score collected after TDS removal during the Challenge Phase will be assessed. Provided the combined score is 2 or greater, it will then be compared to the skin irritation scores collected during the induction phase. If the last Challenge Phase score is 2 or greater and generally exceeds the skin irritation scores collected during the induction phase, the subject will return for the Re-Challenge phase. | Challenge: Up to 5 days including 2-day TDS application and a 3-day visual scoring of the TDS application site following TDS removal | |
Primary | Number of Subjects with Skin sensitization potential of Corplex TDS (Re-Challenge Phase) | Subject's sensitization potential will be assessed using the combined Dermal Response score (8-point categorical scale using numeric values) and the Other Effects score (6-point categorical scale using alphabet letters equivalent to numeric values). The last of 48 hr or 72 hr score collected after TDS removal during the Re-Challenge phase will be assessed. The subject will be considered for potential sensitization if they meet the same criteria in both Challenge phase and Re-Challenge phase (i.e. a combined score of 2 or greater at the last assessment at 48 hr or 72 hr post patch removal and the score are generally higher compared to induction phase scores. | Re-Challenge: Up to 5 days including 2-day TDS application and a 3-day visual scoring of the TDS application site following TDS removal | |
Secondary | Mean Cumulative Skin Irritation Score of Donepezil Corplex TDS compared to Vehicle TDS (Induction Phase) | Mean cumulative skin irritation will be determined and compared between Corplex Donepezil TDS and Vehicle TDS. Mean Cumulative skin irritation score is determined by averaging the combined Dermal Response score (8-point categorical scale using numeric values) and the Other Effects score (6-point categorical scale using alphabet letters equivalent to numeric values) during the induction phase of the study. | Induction (21 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01806831 -
Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment
|
N/A | |
Completed |
NCT02297841 -
Repeated Insult Patch Test of Personal Lubricants
|
N/A | |
Completed |
NCT02968446 -
Effect of Vitamin D After Application With Valchlor
|
Early Phase 1 | |
Unknown status |
NCT01821274 -
A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design
|
Phase 1 | |
Completed |
NCT01892657 -
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
|
Phase 4 | |
Withdrawn |
NCT02400320 -
Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
|
Phase 4 | |
Not yet recruiting |
NCT02645110 -
Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations
|
N/A | |
Completed |
NCT01887860 -
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
|
N/A | |
Completed |
NCT01887808 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
|
N/A | |
Completed |
NCT01892410 -
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
|
N/A | |
Completed |
NCT01888887 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
|
N/A | |
Completed |
NCT01892423 -
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
|
N/A |